Monoclonal Antibody for CD19 CAR-T Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting CAR positive cells, such as qPCR and existing reagents, suffer from low sensitivity, inaccurate differentiation between CAR-positive T cells and B cells, and inability to simultaneously detect multiple surface markers, limiting their application in CAR-T drug quality control and clinical treatment.
Innovation Solution
Development of a monoclonal antibody with high specificity and affinity, specifically targeting the extracellular antigen binding region of CD19 CAR, which forms the basis of a detection reagent with enhanced sensitivity and accuracy for detecting CD19 CAR positive cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If qPCR method is used to detect CAR gene positive T cells, then the detection process is simple, but the accuracy is reduced due to false positives from T cells integrated with CAR gene but not normally expressing CAR
Solution Approach 1:
The patent replaces the molecular biology-based qPCR method with an immunological detection method using monoclonal antibodies. The antibody-based approach directly detects CAR protein expression on cell surfaces, eliminating the false positives associated with qPCR's indirect gene detection, while maintaining operational simplicity through standard flow cytometry or ELISA techniques.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary detection reagents that specifically bind to CAR proteins on cell surfaces. This intermediary approach allows for accurate differentiation between CAR-positive T cells and CAR-positive B cells, resolving the accuracy issue of qPCR while keeping the detection process accessible through conventional immunological methods.
2Ease of operation
If qPCR method is used to detect CAR positive cells, then the detection process is straightforward, but the ability to distinguish CAR-positive T cells from CAR-positive B cells is lost
Solution Approach 1:
The patent applies local quality by using monoclonal antibodies with specific epitope recognition to differentiate between cell types. The antibodies are designed to recognize specific CAR variants or cell surface markers that are uniquely expressed on T cells or B cells, enabling reliable differentiation while maintaining operational simplicity through standard immunological assays.
Solution Approach 2:
The patent employs monoclonal antibodies as intermediary reagents that mediate specific recognition between detection systems and target cells. These antibodies serve as selective intermediaries that can distinguish between CAR-positive T cells and CAR-positive B cells based on their unique surface characteristics, providing reliable cell type differentiation without complicating the detection process.
3Adaptability or versatility
If existing detection reagents are used, then the detection process is available, but the detection sensitivity is insufficient for in vivo application
Solution Approach 1:
The patent applies parameter changes by optimizing antibody characteristics such as affinity, specificity, and concentration to enhance detection sensitivity. The monoclonal antibodies are engineered with high affinity binding to CAR proteins, enabling detection at lower expression levels and in complex biological samples like in vivo tissues, while maintaining reagent availability through standardized production methods.
Solution Approach 2:
The patent uses monoclonal antibodies as standardized copies of detection reagents that can be produced consistently through cell line culture. These standardized antibody copies provide reliable and sensitive detection across different applications, including in vivo studies, while maintaining availability through reproducible manufacturing processes.
4Adaptability or versatility
If existing detection reagents are used, then detection is possible, but the discrimination between positive and negative cells is insufficient
Solution Approach 1:
The patent applies local quality by designing monoclonal antibodies with highly specific epitope recognition that targets unique features of CAR-positive cells. This specificity enables clear discrimination between positive and negative cells with minimal overlap in detection signals, while the antibodies remain applicable across various cell types and detection scenarios through standardized immunological methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody-based detection reagent achieves a detection sensitivity of ≥1 CD19 CAR positive cell/1000 cells, offering high discrimination between positive and negative cells, and is more accurate than existing methods, meeting the requirements for CAR-T drug quality control and clinical treatment monitoring.
Implementation Method 1
The invention provides a heavy chain variable region of an antibody, a light chain variable region of an antibody, and a monoclonal antibody against CD19 antibody... the monoclonal antibody specifically binds to the extracellular antigen binding domain of CD19 CAR
Data Source
AI summary
Provided are a monoclonal antibody against CD19 antibody and the application thereof. The monoclonal antibody which targets CD 19 antibody has high specificity and strong affinity. Also provided are a detection reagent with high sensitivity, good accuracy and good specificity for the detection of CAR-T cells and a detection method using the detection reagent, which may directly target an extracellular antigen-binding region on the CAR-T cell.